Nevirapine Vocate (Nevirapine)

Nevirapine binds to a non‑catalytic site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s activity. This prevents the conversion of viral RNA into DNA, thereby inhibiting viral replication.

The dosing regimen for nevirapine is individualized by the prescribing clinician based on the patient’s clinical status, weight, and other medications. Only a qualified healthcare professional should determine the appropriate dose.

Nevirapine may be used in pregnancy when the benefits outweigh potential risks, particularly for preventing mother‑to‑child transmission of HIV. Safety during breastfeeding is not fully established; clinicians should assess risks and counsel patients accordingly.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Nevirapine belongs to the NNRTI class, offering a once‑daily oral option with a well‑characterized resistance profile. Compared with efavirenz, another NNRTI, nevirapine may have a lower incidence of central nervous system side effects but carries a higher risk of skin and hepatic reactions.

Nevirapine Vocate should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain stability.

Nevirapine Vocate is taken orally, usually with food or a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening hepatic failure. Prompt medical attention is required if symptoms like rash, jaundice, or flu‑like illness develop.

Nevirapine is contraindicated in patients with a known hypersensitivity to nevirapine or any component of the formulation, and in those with pre‑existing severe liver disease. Caution is also advised for individuals with a history of severe skin reactions.